Pinnacle Wealth Planning Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$6.06K	Buy	101 +14	+16%	+$882	﹤0.01%	2250
2026 Q2	$4.98K	Buy	87 +19	+28%	+$1.04K	﹤0.01%	2293
2026 Q1	$3.84K	Buy	68 +5	+8%	+$292	﹤0.01%	2314
2025 Q4	$3.74K	Buy	+63	New	+$3.43K	﹤0.01%	2349
2021 Q1	–	Sell	-1,322	Closed	-$116K	–	557
2020 Q4	$116K	Buy	+1,322	New	+$105K	0.03%	414

Other funds holding BMRN

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

ARGA Investment Management Stamford, Connecticut $3.94B AUM 28.9% 1-Year Est. Return

Edmond de Rothschild Holding Chambesy, Switzerland $8.18B AUM 23.81% 1-Year Est. Return

Pinnacle Wealth Planning Services's BMRN Position: Q3 2026 in Review

Pinnacle Wealth Planning Services increased its BioMarin Pharmaceuticals (BMRN) stake by 16% in Q3 2026, buying an estimated $882 and bringing the position to 101 shares worth $6.06K. The position accounts for ﹤0.01% of the portfolio, ranked #2250.

Pinnacle Wealth Planning Services first reported a position in BMRN in Q4 2020 and has held it in 5 quarters since. The position peaked at $116K in Q4 2020. 308 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

Pinnacle Wealth Planning Services held 101 shares of BioMarin Pharmaceuticals worth $6.06K as of Q3 2026.
Pinnacle Wealth Planning Services bought 14 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $882.
BioMarin Pharmaceuticals made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q3 2026, its #2250 holding.
Pinnacle Wealth Planning Services first reported a position in BioMarin Pharmaceuticals in Q4 2020 and has held it in 5 quarters since.
Pinnacle Wealth Planning Services's BioMarin Pharmaceuticals position peaked at $116K in Q4 2020.
308 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q3 2026, filed 27 Oct 2026.